ArticleSkin appendage disorders2023
Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review.
Article in Skin appendage disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Evaluating the Effectiveness of Commercial Oral Supplements for Hair Growth: A Systematic Review and Meta-Analysis.Journal of cosmetic dermatology · 2026Pooled it
- Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review.Frontiers in pharmacology · 2025Pooled it
- Effectiveness of platelet-rich plasma in treating female hair loss: A systematic review and meta-analysis of randomized controlled trials.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Pooled it
- Blood pressure changes in patients after Minoxidil microinfusion to treat female pattern alopecia: analysis of a randomized, single blinded, placebo controlled clinical trial.Archives of dermatological research · 2025Trial
- In vitro and in vivo models for androgenetic alopecia drug development.Disease models & mechanisms · 2026Review
- A Novel Approach Combining Ultrasound-Induced Drug-Free Vasodilation and Photoacoustic Monitoring of Vascular Responses.Annals of biomedical engineering · 2026Article
- Topical Minoxidil and Low-Dose Oral Minoxidil in Onychodystrophy: A Proposed Treatment Algorithm.Journal of cosmetic dermatology · 2026Review
- Evaluation of Hypoxia-Conditioned MSC Exosomes' Effects on GM-CSF and IL-1α Expression in a Rat Model of Androgenic Alopecia.Medeniyet medical journal · 2026Article
- No Association between Patient Demographics and Adverse Effects of Low-Dose Oral Minoxidil in a Retrospective Cohort study of Nonscarring Alopecia Patients.Dermatology practical & conceptual · 2026Article
- Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.American journal of clinical dermatology · 2026Review
- A Comprehensive Review on the Efficacy of Antihypertensives in Patients With End-Stage Renal Disease.International journal of hypertension · 2026Review
- Minoxidil May be a Partial Agonist of Estrogen Receptor Alpha.microPublication biology · 2026Article
- Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia.Frontiers in pharmacology · 2026Review
- Fractional microporation-guided delivery of nanoencapsulated drugs for enhanced cutaneous and follicular absorption: a comparison of ablative laser and radiofrequency microneedling.Drug delivery and translational research · 2026Article
- Development of a sensor-compatible vascular microphysiological system for metabolic monitoring during drug-induced endothelial injury.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Article
- Gender Differences in Adverse Effects and Dosing Practices of Low-Dose Oral Minoxidil for Androgenetic Alopecia: A Retrospective Analysis of 310 Patients.Skin appendage disorders · 2025Article
- Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review.Journal of clinical medicine · 2025Review
- Consensus Recommendations for the Management of Androgenetic Alopecia in Egypt: A Modified Delphi Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Low-Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions.Journal of cosmetic dermatology · 2025Article
- A bibliometric analysis of alternative drug therapy options in the treatment of androgenetic alopecia.Journal of cosmetic dermatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-dose oral minoxidil (LDOM) has demonstrated a promising safety and efficacy profile in the treatment of various hair disorders, including male androgenetic alopecia (AGA) and female-pattern hair loss (FPHL); however, it lacks FDA approval. The usual LDOM starting dose for male AGA is 1-5 mg/day, depending on physician preference and the patient's condition. For FPHL, it is 0.5-1 mg/day. The maximum dose is generally 5 mg/day. If patients respond well without major side effects, the dose may be gradually increased since the LDOM's efficacy appears to be dose-dependent. Patients may use LDOM long term if the treatment outcome is satisfactory. The common side effects of LDOM are hypertrichosis and cardiovascular symptoms. Females are more prone to hypertrichosis than males. The side effects of LDOM can be categorized as (a) dose-dependent type A side effects (hypertrichosis and cardiovascular symptoms) and (b) idiosyncratic type B side effects (pericardial effusion). Minoxidil acts via multiple pathways. Although minoxidil has a relatively short half-life of around 4 h, its hypotensive effect may last approximately 72 h. Effective treatments for alopecia are limited. Therefore, LDOM could be an important addition to the available therapies for managing some hair disorders, including AGA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.